Ultragenyx Pharmaceutical INC (RARE) Holding Held by Capital International Investors

Investors sentiment decreased to 1.5 in Q2 2019. Its down 1.08, from 2.58 in 2019Q1. It worsened, as 20 investors sold RARE shares while 36 reduced holdings. 23 funds opened positions while 61 raised stakes. 57.68 million shares or 0.70% more from 57.27 million shares in 2019Q1 were reported. New York State Common Retirement Fund holds 0% or 56,000 shares in its portfolio. Voya Investment Mngmt Ltd Liability Co holds 0.04% or 270,476 shares. Commercial Bank Of New York Mellon reported 0% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Rhumbline Advisers reported 81,995 shares. Rmb Capital Mngmt Limited Liability Com reported 26,803 shares stake. Assetmark Inc has invested 0% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). 5.62 million were reported by Cap Invsts. The United Kingdom-based Pictet Asset Mngmt Limited has invested 0.04% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Suntrust Banks has 4,843 shares. Moreover, Rothschild Asset Us has 0.07% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Dimensional Fund Advsrs LP reported 0% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Shell Asset Mngmt Communication holds 0.01% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 5,184 shares. Metropolitan Life Insurance New York holds 16,653 shares. California State Teachers Retirement System accumulated 0.01% or 84,135 shares. Loomis Sayles Lp reported 219,254 shares stake.

Capital International Investors increased its stake in Ultragenyx Pharmaceutical Inc (RARE) by 0.9% based on its latest 2019Q2 regulatory filing with the SEC. Capital International Investors bought 50,013 shares as the company’s stock declined 6.08% . The institutional investor held 5.62M shares of the major pharmaceuticals company at the end of 2019Q2, valued at $356.78 million, up from 5.57M at the end of the previous reported quarter. Capital International Investors who had been investing in Ultragenyx Pharmaceutical Inc for a number of months, seems to be bullish on the $2.54 billion market cap company. The stock decreased 1.32% or $0.59 during the last trading session, reaching $44.1. About 805,509 shares traded or 63.90% up from the average. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 22.30% since September 13, 2018 and is downtrending. It has underperformed by 22.30% the S&P500.

Capital International Investors, which manages about $250.64B US Long portfolio, decreased its stake in Toronto Dominion Bank (The) (NYSE:TD) by 1.31M shares to 4.40M shares, valued at $257.01 million in 2019Q2, according to the filing. It also reduced its holding in Jpmorgan Chase And Co (NYSE:JPM) by 570,371 shares in the quarter, leaving it with 23.15M shares, and cut its stake in Linde Plc.

More notable recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Nasdaq.com which released: “Tianjin Binhai New Area Construction revives bond issue – Nasdaq” on September 12, 2019, also Nasdaq.com with their article: “China’s Minmetals says to close rare earth unit after pollution violations – Nasdaq” published on August 15, 2019, Nasdaq.com published: “Assertio Therapeutics Enters Oversold Territory – Nasdaq” on August 20, 2019. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) were released by: Nasdaq.com and their article: “eHealth Enters Oversold Territory – Nasdaq” published on September 12, 2019 as well as Nasdaq.com‘s news article titled: “The Microbiome Therapeutic and Diagnostic Market – Nasdaq” with publication date: September 12, 2019.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Ratings Coverage

Among 2 analysts covering Ultragenyx Pharmaceutical (NASDAQ:RARE), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ultragenyx Pharmaceutical has $83 highest and $7500 lowest target. $77’s average target is 74.60% above currents $44.1 stock price. Ultragenyx Pharmaceutical had 5 analyst reports since March 15, 2019 according to SRatingsIntel. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Outperform” rating by Wedbush on Friday, August 2. Morgan Stanley maintained the shares of RARE in report on Friday, August 2 with “Overweight” rating. The firm earned “Overweight” rating on Wednesday, March 27 by Morgan Stanley.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.